ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

NCT05653271 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma
Non Hodgkin Lymphoma
DLBCL
Primary Mediastinal Large B Cell Lymphoma
Marginal Zone Lymphoma
Follicular Lymphoma
Burkitt Lymphoma
High-grade B-cell Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: ACE1831
DRUG: Obinutuzumab

Sponsor

Acepodia Biotech, Inc.